12 May 2026

Intermittent Fasting in 2026: What the Evidence Actually Says

Key Takeaways

Intermittent fasting dominated the weight loss conversation for a decade. Now it's time for an honest assessment — where it works, where it doesn't, and how it compares to GLP-1 medications.

Intermittent Fasting Has Had Its Moment. What Does the Evidence Actually Say?

Intermittent fasting dominated the weight loss conversation for the better part of a decade. 5:2, 16:8, OMAD — the frameworks multiplied, the books sold, and the before-and-after photos circulated. Now, with GLP-1 medications producing 15–20% body weight loss in clinical trials, the conversation has shifted. But that doesn't mean the intermittent fasting research is worthless. It means it's time for an honest assessment of what it actually does and doesn't do.

This article reviews the current evidence for intermittent fasting in 2026 — including where it works, where it doesn't, how it compares to continuous calorie restriction, and how it stacks up against pharmacological approaches.

What Is Intermittent Fasting?

Intermittent fasting (IF) is a broad term covering several distinct eating patterns that cycle between periods of eating and fasting. The main approaches studied in clinical research are:

Time-restricted eating (TRE): Confining all eating to a specific daily window — most commonly 8 hours eating, 16 hours fasting (16:8). No specific calorie targets.
Alternate-day fasting (ADF): Alternating between normal eating days and severely restricted days (typically 500 calories or complete fast).
5:2 diet: Five days of normal eating, two non-consecutive days of severe calorie restriction (500–600 calories). A hybrid of ADF and TRE.
Prolonged fasting: Multi-day fasting periods, typically only studied in clinical settings.

What the Evidence Shows: Weight Loss

The most comprehensive systematic reviews and meta-analyses of intermittent fasting draw a consistent conclusion: intermittent fasting produces similar weight loss to continuous calorie restriction when total calorie intake is matched.

A widely cited 2022 trial published in the New England Journal of Medicine compared time-restricted eating (8-hour eating window) to a standard three-meals-a-day pattern in patients with obesity and metabolic syndrome. After 12 months, both groups lost a similar amount of weight — approximately 6–7kg — and showed similar improvements in metabolic markers.

Average weight loss figures from the most robust IF trials:

Time-restricted eating (16:8): 3–5% of body weight over 8–24 weeks
5:2 diet: 4–8% of body weight over 12–24 weeks
Alternate-day fasting: 4–8% of body weight over 12–24 weeks

These are real, meaningful results for a dietary intervention. They are also substantially lower than the 15–20% average body weight loss produced by semaglutide or tirzepatide in clinical trials.

Ready to speak with an Australian GP about weight loss?

Request a bulk billed telehealth weight loss consultation. No referral required.

Request an Appointment

Where Intermittent Fasting Shows Genuine Promise

Metabolic Health Beyond Weight Loss

Some of the more interesting IF research concerns metabolic effects that appear to be partially independent of weight loss. Multiple studies have shown improvements in fasting insulin, insulin sensitivity, and inflammatory markers in people following IF protocols.

Adherence for Some Personality Types

One consistent finding in IF research is that some people find it genuinely easier to adhere to time-restricted eating than to continuous calorie counting. Adherence is the primary predictor of real-world dietary intervention success — a diet that produces 8% weight loss in trials but 0% in practice because people can't stick to it is less useful than a 4% intervention people actually follow.

Combination with Other Interventions

IF combined with resistance training has shown promising results for body composition specifically — some trials show greater preservation of lean muscle mass and greater reduction in fat mass compared to continuous calorie restriction, though the evidence here is mixed.

Where the Evidence Is Weak or Overstated

Long-Term Maintenance

The same limitation that applies to all dietary interventions applies to IF: weight is typically regained when the behaviour stops. There is no strong evidence that IF produces meaningfully better weight maintenance over 2–5 years compared to other calorie-restricted approaches.

Not Suitable for Everyone

IF is contraindicated or requires careful management in people with a history of eating disorders, people with type 1 or type 2 diabetes on insulin or sulfonylureas, pregnant or breastfeeding women, and people who are underweight.

Intermittent Fasting vs GLP-1 Medications: An Honest Comparison

	Intermittent Fasting	GLP-1 Medications (Wegovy/Mounjaro)
Average weight loss	3–8% body weight	15–20% body weight
Cost	Nil	$350–$750/month (private prescription)
Prescription required	No	Yes
Side effects	Hunger, irritability, headache (usually transient)	Nausea, GI symptoms (usually transient)
Suitable for BMI 25–29 without comorbidities	Yes	Generally outside TGA indication

The Honest Takeaway

Intermittent fasting is a legitimate, evidence-based dietary strategy that produces real weight loss and metabolic improvements for many people. It is free, accessible, and works well for people who find it practically compatible with their lifestyle and who need to lose a modest amount of weight without metabolic complications.

For people with significant obesity (BMI ≥30), or overweight with metabolic comorbidities, the evidence now strongly favours GLP-1 pharmacotherapy as an adjunct to lifestyle modification. IF and GLP-1 medications are not mutually exclusive — dietary patterns consistent with IF principles can complement pharmacological treatment.

A GP is the right person to help you decide which approach, or which combination, makes sense for your individual situation. Telehealth GP consultations for weight management can be bulk billed under Medicare for eligible patients.